gyrA Mutations in Mycoplasma genitalium and Their Contribution to Moxifloxacin Failure: Time for the Next Generation of Resistance-Guided Therapy
Clinical Infectious Diseases · 16.06.2023 · 76 (12) · 2187-2195
DOI: 10.1093/cid/ciad057 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 01.02.2023. Verfasst von Gerald L Murray und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynaecology, The University of Melbourne, Parkville, Victoria, Australia. Hauptthemen laut MEDLINE: Mycoplasma genitalium, Mycoplasma Infections. Die Arbeit wurde bisher 57-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: an Australian Research Council, National Health and Medical Research Council.
Abstract (Originalsprache)
Background
Although single nucleotide polymorphisms (SNPs) in Mycoplasma genitalium parC contribute to fluoroquinolone treatment failure, data are limited for the homologous gene, gyrA. This study investigated the prevalence of gyrA SNPs and their contribution to fluoroquinolone failure.
Methods
Samples from 411 patients (male and female) undergoing treatment for M. genitalium infection (Melbourne Sexual Health Centre, March 2019–February 2020) were analyzed by Sanger sequencing (gyrA and parC). For patients treated with moxifloxacin (n = 194), the association between SNPs and microbiologic treatment outcome was analyzed.
Results
The most common parC SNP was G248T/S83I (21.1% of samples), followed by D87N (2.3%). The most common gyrA SNP was G285A/M95I (7.1%). Dual parC/gyrA SNPs were found in 8.6% of cases. One third of infections harboring parC G248T/S83I SNP had a concurrent SNP in gyrA conferring M95I. SNPs in gyrA cooccurred with parC S83I variations. Treatment failure was higher in patients with parC S83I/gyrA dual SNPs when compared with infections with single S83I SNP alone from analysis of (1) 194 cases in this study (81.2% vs 45.8%, P = .047), and (2) pooled analysis of a larger population of 535 cases (80.6% vs 43.2%; P = .0027), indicating a strong additive effect.
Conclusions
Compared with parC S83I SNP alone, M. genitalium infections with dual mutations affecting parC/gyrA had twice the likelihood of failing moxifloxacin. Although antimicrobial resistance varies by region globally, these data indicate that gyrA should be considered as a target for future resistance assays in Australasia. We propose a strategy for the next generation of resistance-guided therapy incorporating parC and gyrA testing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynaecology, The University of Melbourne, Parkville, Victoria, Australia.
- Women's Centre for Infectious Diseases, The Royal Women's Hospital, Parkville, Victoria, Australia.
- Murdoch Children's Research Institute, Parkville, Victoria, Australia.
- Melbourne Sexual Health Centre, Alfred Health, Carlton, Victoria, Australia.
- Central Clinical School, Monash University, Melbourne, Victoria, Australia.
- Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia.
ORCID-Profile: Gerald L Murray
Förderung
- an Australian Research Council
- National Health and Medical Research Council
Zitieren
APA
Murray, G. L., Plummer, E. L., Bodiyabadu, K., Vodstrcil, L. A., Huaman, J. L., Danielewski, J. A., Chua, T. P., Machalek, D. A., Garland, S., Doyle, M., Sweeney, E. L., Whiley, D. M., & Bradshaw, C. S. (2023). gyrA Mutations in Mycoplasma genitalium and Their Contribution to Moxifloxacin Failure: Time for the Next Generation of Resistance-Guided Therapy. Clinical Infectious Diseases, 76(12), 2187-2195. https://doi.org/10.1093/cid/ciad057
Vancouver
Murray GL, Plummer EL, Bodiyabadu K, Vodstrcil LA, Huaman JL, Danielewski JA, et al. gyrA Mutations in Mycoplasma genitalium and Their Contribution to Moxifloxacin Failure: Time for the Next Generation of Resistance-Guided Therapy. Clinical Infectious Diseases. 2023;76(12):2187-2195. doi:10.1093/cid/ciad057
BibTeX
@article{Murray2023,
author = {Murray, Gerald L and Plummer, Erica L and Bodiyabadu, Kaveesha and Vodstrcil, Lenka A and Huaman, Jose L and Danielewski, Jennifer A and Chua, Teck Phui and Machalek, Dorothy A and Garland, Suzanne and Doyle, Michelle and Sweeney, Emma L and Whiley, David M and Bradshaw, Catriona S},
title = {gyrA Mutations in Mycoplasma genitalium and Their Contribution to Moxifloxacin Failure: Time for the Next Generation of Resistance-Guided Therapy},
journal = {Clinical Infectious Diseases},
year = {2023},
volume = {76},
number = {12},
pages = {2187--2195},
doi = {10.1093/cid/ciad057}
}
EUVIMED